Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroGen, Inc - Common Stock (NQ:FGEN)

10.85 -0.27 (-2.43%)
Streaming Delayed Price Updated: 9:45 AM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about FibroGen, Inc - Common Stock

< Previous 1 2 3 Next >
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
Via AB Newswire
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Fibrogen, Inc. and Encourages Investors With Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why did Sarepta Therapeutics Stock Plummet?
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating. 
Via MarketBeat
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
From Kahn Swick & Foti, LLC
Via Business Wire
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
From Kahn Swick & Foti, LLC
Via Business Wire
FibroGen, Inc. (NASDAQ:FGEN) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 06/24/2022 -- An investigation was announced for current long-term investors in shares of FibroGen, Inc. (NASDAQ:FGEN) over potential breaches of fiduciary duties by... 
Via SBWire
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN
From Kahn Swick & Foti, LLC
Via Business Wire
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN
From Kahn Swick & Foti, LLC
Via Business Wire
NASDAQ:FGEN Long Term Investor Notice: Lawsuit Filed Against Certain Directors of FibroGen, Inc
San Diego, CA -- (SBWIRE) -- 05/05/2022 -- An investor in FibroGen, Inc. (NASDAQ:FGEN) shares filed a lawsuit against certain directors of FibroGen, Inc over alleged breaches of fiduciary duties. 
Via SBWire
FIBROGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of FibroGen, Inc. - FGEN
From Kahn Swick & Foti, LLC
Via Business Wire
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. Is Investigating Fibrogen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NASDAQ: FGEN Long Term Investor Alert: Investigation of Potential Wrongdoing at FibroGen, Inc.
San Diego, CA -- (SBWIRE) -- 08/20/2021 -- An investigation on behalf of current long term investors in FibroGen, Inc. (NASDAQ: FGEN) shares over possible breaches of fiduciary duty by certain officers... 
Via SBWire
Topics Lawsuit
DEADLINE TODAY: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
FIBROGEN CLASS ACTION REMINDER
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
DEADLINE TOMORROW: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against FibroGen, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
FIBROGEN SHAREHOLDER NOTICE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
FGEN Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors or June 11, 2021 Deadline in Securities Fraud Class Action Lawsuit
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
From The Law Offices of Frank R. Cruz
Via Business Wire
FRIDAY DEADLINE NOTICE: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
FIBROGEN 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroGen, Inc. - FGEN
From Kahn Swick & Foti, LLC
Via Business Wire
FIBROGEN SHAREHOLDER ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
FibroGen, Inc. (NASDAQ:FGEN) Investor Notice: Deadline in Lawsuit on June 11, 2021
San Diego, CA -- (SBWIRE) -- 06/08/2021 -- A deadline is coming up on June 11, 2021 in the lawsuit filed for certain investors of FibroGen, Inc. (NASDAQ:FGEN). 
Via SBWire
Topics Lawsuit
FGEN Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
FRIDAY DEADLINE REMINDER: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
FIBROGEN DEADLINE ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
FRIDAY DEADLINE ALERT: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
FIBROGEN UPDATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.